BeautyHealth reported a strong Q4 2022, with net sales increasing by 26% year-over-year to $98.1 million and net income reaching $3.8 million. Adjusted EBITDA also saw a substantial increase of 92% to $16.3 million. The company's performance was driven by growth in both delivery systems and consumables, with notable contributions from the Americas and APAC regions.
Net sales increased by 26% to $98.1 million compared to Q4 2021.
Delivery Systems net sales increased +19% to $50.7 million.
Consumables net sales increased +35% to $47.4 million compared to Q4 2021.
Adjusted EBITDA increased +92% to $16.3 million compared to Q4 2021.
BeautyHealth expects net sales in the range of $450 to $470 million for fiscal 2023 and reiterates its outlook for fiscal 2023 adjusted EBITDA margin of 18% to 20% and its fiscal 2025 long-range outlook of $600 million to $700 million net sales and 25% to 30% adjusted EBITDA margin.
Visualization of income flow from segment revenue to net income